Interactive Strength, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Interactive Strength, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.53M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.38M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $962.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $681.0K | Apr 1, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $913.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($2.78M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($5.53M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($8.87M) | Apr 1, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.97M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($34.93M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($51.37M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($58.23M) | Apr 1, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($19.86M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($29.19M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($54.48M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($54.35M) | Apr 1, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.92M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $6.99M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $10.04M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $19.96M | Apr 1, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.41M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($14.81M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($15.43M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($35.55M) | Apr 1, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $94.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 31, 2026 |
| FY2023 | Dec 31, 2023 | $0 | Apr 1, 2024 |
| FY2023 | Dec 31, 2022 | $577.0K | Apr 1, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $46.84M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $34.17M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $16.80M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $24.45M | Apr 1, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.15M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $27.06M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $22.35M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $27.18M | Apr 1, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.39M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $7.12M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | ($5.55M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | ($2.73M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($19.66M) | Apr 1, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.55M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $13.22M | Mar 31, 2026 |
| FY2024 | Feb 2, 2024 | $13.20M | Mar 31, 2025 |
| FY2025 | Dec 31, 2023 | $0 | Mar 31, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($227.54M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($202.59M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($166.91M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($115.54M) | Apr 1, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $512.0K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $138.0K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $226.0K | Apr 1, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $11.32M | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $9.81M | Mar 31, 2025 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (171) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (16,328) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (16,614) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (119) | Apr 1, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (171) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (16,328) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (16,614) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | (119) | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 307,516 | Mar 31, 2026 |
| FY2025 | Jun 26, 2025 | 1.41M | Mar 31, 2026 |
| FY2025 | Jun 25, 2025 | 14.09M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 14,021 | Mar 31, 2026 |
| FY2025 | Nov 11, 2024 | 417,870 | Mar 31, 2026 |
| FY2025 | Nov 8, 2024 | 41.79M | Mar 31, 2026 |
| FY2025 | Jun 14, 2024 | 664,526 | Mar 31, 2026 |
| FY2025 | Jun 13, 2024 | 26.58M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 3,548 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 2.45M | Apr 1, 2024 |